Mai Bairui announced the completion of round a financing of 400 million yuan

Yantai mabplex international, a company specializing in the cdmo service of biomacromolecule drugs, announced that it has recently completed the first financing since its establishment, with a financing amount of 400 million yuan, which is also the largest single financing in the field of domestic large molecule cdmo in recent period This round of financing is led by investment institutions such as SDIC venture capital and Shenzhen Venture Capital The financing funds will be used for the upgrading of the technical platform of mabri, the expansion of phase III clinical samples and commercial production capacity of antibody drugs, and the company's international strategic layout In the past 2018, the company has handed over a beautiful report card Following the success of the biopharmaceutical drug production license, the second stage GMP production workshop of the company has been officially opened and 2000 liter cell culture has been carried out The production workshop can reach a maximum of 36 kiloliter cell culture scale, can simultaneously carry out GMP production of multiple biopharmaceutical products, and meet the needs of phase 3 clinical samples and commercial production In terms of international strategy, the research and development center in San Diego, US, has been officially operated in the third quarter of 2018, focusing on the development of antibody and ADC drug process, and has launched a number of development projects Mabri Shanghai R & D center is planned to officially operate in the first quarter of 2019, and will focus on the process development of antibody drugs At the same time, the US and Australian inds declared by Macquarie for customers were approved at one time, and the pace of globalization was further accelerated In recent years, the speed of research and development and marketing of biological drugs in China has been greatly accelerated, the reform of drug review and approval system has been deepened, and start-ups have been emerging However, due to the high cost of research and development and the investment in the construction of production facilities, biological drug research and development has a huge risk As an expert of the overall expert group of the national "major new drug innovation" science and technology major special project, Dr Fang Jianmin, chairman of Macquarie, witnessed the leapfrog development of the domestic biomedical industry in recent years: "Macquarie's vision is to help Biopharmaceutical Enterprises speed up research and development, reduce research and development costs and improve product quality, so as to improve the efficiency of new drug research and development Mabri has established a one-stop service platform for biopharmaceuticals, which is one of the few companies in China specializing in the cdmo service of biopharmaceuticals With the help of our professional services and international standards, R & D enterprises can not only shorten product development time, but also use limited funds for new drug projects, reduce R & D risk and enhance enterprise value This financing will greatly improve the service ability of mabri, and we will continue to provide customers with high-quality services About mabri Yantai maibairui international biomedical Co., Ltd is a company specializing in the cdmo service of biological drugs, with three R & D and production centers in Yantai, Shanghai and Santiago It can provide global customers with the R & D, production, Ind application, clinical sample preparation, and even commercialized GMP of macromolecular biological drugs such as monoclonal antibody, antibody coupled drugs, recombinant protein drugs Production and other one-stop outsourcing services At present, mabri has a production facility of 50000 square meters There are nine single antigen GMP production lines, two ADC original solution production lines, one McAb preparation production line and one ADC preparation production line It can provide GMP production of biological drugs in the scale of 200L to 12000l (6 * 2000L), which can help customers speed up the progress of clinical trials and drug marketing We have a management team with rich international experience and a professional team with perfect organization We have established a strict quality system and GMP production specifications We can complete the ind / BLA application of innovative biological drugs and biological similar drugs according to the requirements of FDA, EMA and nmpa At present, Maberry has provided cdmo services for dozens of pharmaceutical companies around the world, and has completed more than ten ind applications, including those in the United States and Australia, and has provided production services for phase I and phase II clinical trial samples for many customers In the first half of 2019, the company will complete a number of ind applications, most of which are China and the United States With the development of the global layout of the company's business, mabri has embarked on a journey of leapfrog growth to ensure the benefits of patients through the global supply chain network.